CLARITY Act wins another law enforcement endorsement
The Digital Asset Market Clarity (CLARITY) Act received support from the Federal Law Enforcement Officers Association before a key Senate deadline.

Crypto journalist for Grafa, with nearly 10 years of experience covering blockchain, Web3, and NFT gaming trends. MBA & Economics grad.
The Digital Asset Market Clarity (CLARITY) Act received support from the Federal Law Enforcement Officers Association before a key Senate deadline.
Aeris Resources (ASX:AIS) achieved a total group copper equivalent production of 42.1kt for the 2026 financial year.
The United Kingdom said tokenised financial markets could add up to £33 billion (US$44 billion) to annual economic output by 2035.
Vection Technologies (ASX:VR1) secured a $3.2 million order from Italian enterprise information technology services firm Retelit Digital Services.
Reed Smith launched Aquarius, a platform that helps crypto companies comply with the European Union's Markets in Crypto-Assets (MiCA) rules.
Ryman Healthcare (ASX:RYM) reported 325 sales of retirement living occupation right agreements for the quarter ended June 30.
Halliburton (NYSE:HAL) secured major integrated well construction contracts for the GranMorgu deepwater development offshore Suriname, operated by TotalEnergies, covering drilling and completion services under a long-term program.
Clearmind Medicine (NASDAQ:CMND) shared early insights from its ongoing Phase I/IIa trial of CMND-100, an investigational MEAI-based compound being evaluated for alcohol use disorder, following a June 10 webinar with study investigators from Yale and Johns Hopkins.
SLB (NYSE:SLB) announced that its OneSubsea joint venture was awarded a major engineering, procurement and construction contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire, covering subsea production systems for 13 wells.
Ocugen (NASDAQ:OCGN) signed a binding term sheet with Roots Pharmaceutical and strategic partner Al-Dhow International Holding to negotiate an exclusive license for OCU400, its investigational modifier gene therapy for retinitis pigmentosa, across the Middle East and North Africa region.